relapsers

与relapsers相关的网络例句 [注：此内容来源于网络，仅供参考]

Some results also suggest cost-effectiveness below 8400euro/(QALY of re-treatment in nonresponders/relapsers.

一些研究也提示在无应答/复发者中再治疗具有成本效益（低于8400欧元/QALY）。

This is mainly in non-responders rather than relapsers, but there does seem to be an added benefit of that extension.

这主要是针对无应答患者而不是复发的患者。但似乎延长治疗确实有额外的益处。

Overall, 43.5% of patients exhibited SVR, 42.6% were nonresponders and 13.9% were relapsers.

总体上43.5%的患者获得SVR，42.6%为无应答者，13.9%为复发者。

In relapsers and nonresponders, fibrosis benefit equals the treatment period.

对于复发和无应答者，肝纤维化仅在治疗期有好转率。

Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) drop-outs for noncompliance or adverse events and 28 (3.0%) were lost during follow-up.

其中429例（46.5%）为无应答者，298例（32.3%）为复发者，168例（18.2%）因为不依从或不良事件脱落，28例（3.0%）失随访。